

# Ajinkya M Pawar

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6504199/publications.pdf>

Version: 2024-02-01

23  
papers

1,105  
citations

623734

14  
h-index

713466

21  
g-index

23  
all docs

23  
docs citations

23  
times ranked

1702  
citing authors

#	ARTICLE	IF	CITATIONS
1	Using a Simple Prescription Gap to Determine Warfarin Discontinuation Can Lead to Substantial Misclassification. <i>Thrombosis and Haemostasis</i> , 2022, 122, 386-393.	3.4	3
2	Updating International Classification of Diseases 9th Revision to 10th Revision of a Claims-Based Frailty Index. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2021, 76, 1316-1317.	3.6	29
3	Emulating Randomized Clinical Trials With Nonrandomized Real-World Evidence Studies. <i>Circulation</i> , 2021, 143, 1002-1013.	1.6	174
4	Updated Assessment of Cardiovascular Risk in Older Patients With Gout Initiating Febuxostat Versus Allopurinol. <i>Journal of the American Heart Association</i> , 2021, 10, e020045.	3.7	9
5	Comparative Risk of Nonvertebral Fractures Among Patients With Rheumatoid Arthritis Treated With Biologic or Targeted Synthetic Disease-Modifying Antirheumatic Drugs. <i>ACR Open Rheumatology</i> , 2021, 3, 531-539.	2.1	7
6	Frailty and Clinical Outcomes of Direct Oral Anticoagulants Versus Warfarin in Older Adults With Atrial Fibrillation. <i>Annals of Internal Medicine</i> , 2021, 174, 1214-1223.	3.9	48
7	Sodium-Glucose Cotransporter-2 Inhibitors Versus Glucagon-like Peptide-1 Receptor Agonists and the Risk for Cardiovascular Outcomes in Routine Care Patients With Diabetes Across Categories of Cardiovascular Disease. <i>Annals of Internal Medicine</i> , 2021, 174, 1528-1541.	3.9	52
8	Linking the Paul Coverdell National Acute Stroke Program to commercial claims to establish a framework for real-world longitudinal stroke research. <i>Stroke and Vascular Neurology</i> , 2021, , svn-2021-001134.	3.3	0
9	Measuring Frailty in Administrative Claims Data: Comparative Performance of Four Claims-Based Frailty Measures in the U.S. Medicare Data. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2020, 75, 1120-1125.	3.6	82
10	Nonrandomized Real-World Evidence to Support Regulatory Decision Making: Process for a Randomized Trial Replication Project. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 107, 817-826.	4.7	76
11	Outcomes of Common Major Surgical Procedures in Older Adults With and Without Dementia. <i>JAMA Network Open</i> , 2020, 3, e2010395.	5.9	9
12	Risk of admission to hospital for serious infection after initiating tofacitinib versus biologic DMARDs in patients with rheumatoid arthritis: a multidatabase cohort study. <i>Lancet Rheumatology</i> , The, 2020, 2, e84-e98.	3.9	45
13	Validation of a Claims-Based Frailty Index Against Physical Performance and Adverse Health Outcomes in the Health and Retirement Study. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2019, 74, 1271-1276.	3.6	130
14	Risk of serious infections in tocilizumab versus other biologic drugs in patients with rheumatoid arthritis: a multidatabase cohort study. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 456-464.	0.9	139
15	Risk of malignancy associated with use of tocilizumab versus other biologics in patients with rheumatoid arthritis: A multi-database cohort study. <i>Seminars in Arthritis and Rheumatism</i> , 2019, 49, 222-228.	3.4	42
16	Empagliflozin and the Risk of Heart Failure Hospitalization in Routine Clinical Care. <i>Circulation</i> , 2019, 139, 2822-2830.	1.6	167
17	Variation in Prescription Drug Prices by Retail Pharmacy Type. <i>Annals of Internal Medicine</i> , 2019, 171, 605.	3.9	30
18	FRAILTY AND THE COMPARATIVE EFFECTIVENESS AND SAFETY OF SGLT2I AND DPP4I IN OLDER ADULTS WITH TYPE 2 DIABETES. <i>Innovation in Aging</i> , 2019, 3, S582-S582.	0.1	1

#	ARTICLE	IF	CITATIONS
19	FRAILITY AND THE COMPARATIVE EFFECTIVENESS AND SAFETY OF SGLT2I AND GLP1-RA IN OLDER ADULTS WITH TYPE 2 DIABETES. <i>Innovation in Aging</i> , 2019, 3, S582-S582.	0.1	0
20	FRAILITY AND THE COMPARATIVE EFFECTIVENESS AND SAFETY OF SGLT2I AND SULFONYLUREA IN OLDER ADULTS WITH TYPE 2 DIABETES. <i>Innovation in Aging</i> , 2019, 3, S581-S581.	0.1	1
21	COMPARATIVE PERFORMANCE OF FOUR CLAIMS-BASED FRAILITY MEASURES IN THE UNITED STATES MEDICARE DATA. <i>Innovation in Aging</i> , 2019, 3, S684-S685.	0.1	1
22	Predictors of Drug Shortages and Association with Generic Drug Prices: A Retrospective Cohort Study. <i>Value in Health</i> , 2018, 21, 1286-1290.	0.3	39
23	Social Media Impact of the Food and Drug Administration's Drug Safety Communication Messaging About Zolpidem: Mixed-Methods Analysis. <i>JMIR Public Health and Surveillance</i> , 2018, 4, e1.	2.6	21